If You Invested in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (also referred to as Olema Oncology) is a clinical-stage biopharmaceutical company listed on the Nasdaq Global Select Market under the ticker symbol OLMA. The company is focused on the discovery, development, and commercialization of targeted therapies for breast cancer and other endocrine-driven cancers. Olema describes its mission as improving outcomes for patients living with breast cancer and beyond by advancing a pipeline of novel therapies informed by a deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.

According to company disclosures, Olema is headquartered in San Francisco, California, and has operations in Cambridge, Massachusetts. It operates within the pharmaceutical preparation manufacturing industry and the broader manufacturing sector, with activities centered on clinical research and development of oncology drug candidates rather than commercial-scale manufacturing at this stage.

Business focus and therapeutic area

Olema’s work is concentrated on estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company emphasizes endocrine-driven cancers and nuclear receptor biology, aiming to address mechanisms of acquired resistance that can limit the effectiveness of existing endocrine therapies. Its programs are designed to target the estrogen receptor pathway and related epigenetic mechanisms that are dysregulated in breast and other cancers.

Lead product candidate: palazestrant (OP-1250)

Olema’s lead product candidate is palazestrant (OP-1250), which the company describes as a proprietary, orally available small molecule with dual activity as a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). Palazestrant is being investigated in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer. In clinical studies cited by the company, palazestrant has been shown to completely block estrogen receptor-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and to demonstrate anti-tumor efficacy with pharmacokinetics and exposure that the company characterizes as attractive, along with favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.

Palazestrant is being evaluated in multiple clinical settings. Olema reports that palazestrant is under investigation as a single agent in a pivotal Phase 3 clinical trial known as OPERA-01, which evaluates monotherapy in second- and third-line ER+/HER2- metastatic breast cancer. In addition, palazestrant is being studied in combination with ribociclib in another pivotal Phase 3 trial, OPERA-02, in the frontline ER+/HER2- metastatic breast cancer setting. The company has also conducted a Phase 1b/2 study of palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer, reporting updated data that support the ongoing Phase 3 combination trial.

Beyond these pivotal studies, palazestrant is being evaluated in multiple Phase 1/2 combination studies with other agents. Olema notes that palazestrant is being tested in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib, reflecting a focus on how palazestrant may be used with CDK4/6 inhibitors and other targeted therapies in ER+/HER2- metastatic breast cancer.

Regulatory designations and collaborations

The company states that palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy, with at least one line given in combination with a CDK4/6 inhibitor. This designation is intended to facilitate the development and review of palazestrant in this setting.

Olema has also entered into clinical trial collaboration and supply agreements. In particular, the company reports an agreement with Pfizer Inc. to evaluate the safety and combinability of palazestrant plus atirmociclib, Pfizer’s investigational, highly selective CDK4 inhibitor, in a Phase 1b/2 study in patients with ER+/HER2- metastatic breast cancer. Under this agreement, Pfizer supplies atirmociclib for use in the study, Olema leads the conduct of the study, and clinical data and inventions relating to the combined use of atirmociclib and palazestrant are jointly owned, with Olema retaining full global commercial and marketing rights to palazestrant. Olema notes that this is its second clinical trial agreement with Pfizer, following an earlier agreement to evaluate palazestrant in combination with palbociclib (IBRANCE) in recurrent, locally advanced or metastatic ER+/HER2- breast cancer.

Pipeline beyond palazestrant: OP-3136

In addition to palazestrant, Olema is developing OP-3136, which the company describes as a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is reported to be dysregulated in breast and other cancers. In preclinical studies summarized by Olema, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and has shown combinability and synergy with endocrine therapies, including palazestrant, and with CDK4/6 inhibitors.

The Investigational New Drug (IND) application for OP-3136 was cleared by the FDA, and Olema reports that patients are enrolling in a Phase 1 clinical study. This study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant in participants with advanced solid tumors. OP-3136 is therefore positioned in the company’s pipeline as a KAT6 inhibitor program that may be used both alone and in combination regimens.

Clinical development activities

Olema’s disclosures highlight extensive clinical development activity around palazestrant. The company is conducting:

• The OPERA-01 pivotal Phase 3 trial evaluating palazestrant monotherapy in second- and third-line ER+/HER2- metastatic breast cancer.
• The OPERA-02 pivotal Phase 3 trial evaluating palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer.
• Phase 1/2 studies of palazestrant in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib in ER+/HER2- advanced or metastatic breast cancer.
• A Phase 1 study of OP-3136 as monotherapy and in combination with fulvestrant and palazestrant in participants with advanced solid tumors.

Updated data from the Phase 1b/2 study of palazestrant plus ribociclib in ER+/HER2- advanced or metastatic breast cancer have been presented, including measures such as median progression-free survival and safety outcomes, and Olema indicates that these data support the ongoing OPERA-02 Phase 3 trial.

Capital markets and listing

Olema Pharmaceuticals, Inc. is registered under Section 12(b) of the Securities Exchange Act of 1934, with its common stock trading on The Nasdaq Global Select Market under the symbol OLMA. The company has used public equity offerings to fund its operations and clinical programs. For example, Olema has disclosed an underwritten public offering of its common stock, conducted pursuant to an effective shelf registration statement on Form S-3 and related prospectus supplements, and has also reported the termination of an at-the-market (ATM) prospectus under a sales agreement with TD Securities (USA) LLC, while leaving the underlying sales agreement in place.

In addition, Olema has reported inducement grants of stock options to new employees under its 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These stock options typically vest over four years and have a 10-year term, with exercise prices set at the last reported sale price of the company’s common stock on the date of grant, as reported by Nasdaq.

Financial reporting and non-GAAP metrics

Olema provides periodic financial results, including research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities balances. The company presents both GAAP and non-GAAP financial measures. Non-GAAP research and development expense is defined by Olema as GAAP R&D expense excluding stock-based compensation expense, and non-GAAP general and administrative expense is defined as GAAP G&A expense excluding stock-based compensation expense. Olema states that it uses these non-GAAP measures to evaluate ongoing operations and for internal planning and forecasting, while noting that such measures are supplemental and should be considered alongside GAAP results.

Position within the biopharmaceutical sector

Within the pharmaceutical preparation manufacturing industry, Olema is positioned as a clinical-stage biopharmaceutical company focused on targeted oncology therapies, particularly for ER+/HER2- metastatic breast cancer. Its strategy, as described in company materials, centers on leveraging expertise in endocrine-driven cancers, nuclear receptor signaling, and epigenetic targets to develop therapies such as palazestrant and OP-3136. The company’s collaborations, regulatory designations, and multi-trial development program reflect its focus on establishing palazestrant as a potential backbone endocrine therapy in combination with other agents, while advancing OP-3136 as a KAT6 inhibitor program that may complement endocrine and CDK4/6-directed treatments.

FAQs about Olema Pharmaceuticals, Inc. (Olema Oncology)